---
uid: Z-001-1150
type: zettel
title: PCA Metabolomics Dimensionality Reduction
aliases: [Z-001-1150, PCA-Metabolomics]
domain: 001
domain-name: Metabolomics Analysis
tags: [zettel, pca, metabolomics, dimensionality-reduction]
parent-moc: [[MOC-Insulin-Signaling]]
source-litnote: [[LitNote_Statistical_Analysis_Omics_L-001-0617]
extraction-date: 2026-04-15
confidence: high
created: 2026-03-08
---

source-litnote: "[[CGPT_0475_Metabolic_Biomarkers_for_Insulin_L-001-0709]]"
# PCA  Dimensionality Reduction
## Related Zettels from Same Source

- [[Multivariate_Analysis_PLS_OPLS_Regression_Z-001-1151]]
- [[Power_Analysis_Sample_Size_METHAP_Z-001-1149]]
- [[Validation_Cross_Validation_Model_Robustness_Z-001-1152]]

## Source

[[LitNote_Statistical_Analysis_Omics_L-001-0617]

## Related Zettels from Same Source

- [[Multivariate_Analysis_PLS_OPLS_Regression_Z-001-1151]]
- [[Power_Analysis_Sample_Size_METHAP_Z-001-1149]]
- [[Validation_Cross_Validation_Model_Robustness_Z-001-1152]]

## Status Checklist

- [ ] Source verified and linked
- [ ] Core Principle articulated
- [ ] Mechanism/Key Details present
- [ ] Evidence attached
- [ ] Significance clear
- [ ] Clinical relevance assessed
- [ ] Related zettels connected
- [ ] Lateral connections added
- [ ] RON review pending


## Related Zettels from Same Source

- [[Multivariate_Analysis_PLS_OPLS_Regression_Z-001-1151]]
- [[Power_Analysis_Sample_Size_METHAP_Z-001-1149]]
- [[Validation_Cross_Validation_Model_Robustness_Z-001-1152]]

## Source

[[LitNote_Statistical_Analysis_Omics_L-001-0617]

## Related Zettels from Same Source

- [[Multivariate_Analysis_PLS_OPLS_Regression_Z-001-1151]]
- [[Power_Analysis_Sample_Size_METHAP_Z-001-1149]]
- [[Validation_Cross_Validation_Model_Robustness_Z-001-1152]]

## Overview
Principal Component Analysis (PCA) reduces the complexity of high-dimensional metabolomics data by transforming correlated variables into uncorrelated principal components—enabling visualization and pattern recognition.

## The Dimensionality Problem

### Metabolomics Data Characteristics
| Feature | Challenge |
|---------|-----------|
| **Variables (p)** | 70+ metabolites (OAT), 20+ fatty acids |
| **Samples (n)** | 220 participants |
| **p >> n risk** | Overfitting potential |
| **Correlation** | Metabolites interrelated |

### Why PCA?
| Benefit | Explanation |
|---------|-------------|
| **Dimension reduction** | Fewer components explain variance |
| **Noise reduction** | Focuses on major patterns |
| **Visualization** | 2D/3D plots of high-dimensional data |
| **Collinearity handling** | Orthogonal components |

## How PCA Works

### Mathematical Concept
```
Original data: X (n × p matrix)
        ↓
PCA transforms to: T (n × k scores) × P' (k × p loadings)
        ↓
Principal components = linear combinations of original variables
```

### Steps
1. **Standardization** — Mean-center and scale variables
2. **Covariance matrix** — Calculate relationships
3. **Eigenvalue decomposition** — Find principal axes
4. **Component selection** — Retain those explaining most variance

## Interpreting PCA Results

### Scree Plot
| Feature | Interpretation |
|---------|----------------|
| **X-axis** | Principal component number |
| **Y-axis** | Eigenvalue (% variance explained) |
| **Elbow point** | Optimal number of components |
| **Typical retention** | PCs explaining >70-80% variance |

### Score Plots
| Use | Interpretation |
|-----|----------------|
| **Samples as points** | Similar samples cluster together |
| **Group separation** | Clear clustering = distinct metabolic profiles |
| **Outliers** | Samples far from cluster center |

### Loading Plots
| Use | Interpretation |
|-----|----------------|
| **Variables as vectors** | Direction = contribution to PC |
| **Magnitude** | Strength of contribution |
| **Groupings** | Metabolites that vary together |

## PCA in METHAP

### Applications
| Analysis | Purpose |
|----------|---------|
| **Baseline comparison** | Healthy vs IR metabolic patterns |
| **Intervention effect** | Shift in metabolic space post-treatment |
| **Outlier detection** | Identify unusual metabolic profiles |
| **Quality control** | Batch effects, technical variation |

### Expected Patterns
| Observation | Interpretation |
|-------------|----------------|
| **Healthy separate from IR** | Distinct metabolic states |
| **IR-Intervention moves toward Healthy** | Successful metabolic improvement |
| **IR-Control stays in IR cluster** | No spontaneous improvement |

## Limitations of PCA

### Unsupervised Nature
| Issue | Impact |
|-------|--------|
| **No group information** | May miss group-discriminating patterns |
| **Maximum variance** | Not necessarily biologically relevant |
| **Solution** | Use PLS-DA for supervised discrimination |

### Other Considerations
| Limitation | Mitigation |
|------------|------------|
| **Scaling sensitivity** | Auto-scaling recommended |
| **Outlier influence** | Robust PCA variants available |
| **Interpretation complexity** | Combine with pathway analysis |

## Related
- [[Multivariate_Analysis_PLS_OPLS_Regression_Z-001-1151]
- [[Validation_Cross_Validation_Model_Robustness_Z-001-1152]
- 

---
*Source: CGPT-0475 — Metabolic s for insulin resistance*

## RELATED FILES
- [[Methylation_Family_[B-004-0001]|Biomarker Family]
- /Metabolic_IR_Family_[B-005-0001]|Biomarker Family Guide]
- 


---

## Significance

| **p >> n risk** | Overfitting potential |

## Connection to Vault

- Up: [[MOC-Insulin-Signaling]]
- Related: [[MOC-Metabolic-Syndrome]], [[MOC-Metabolomics]]

---
parent-index: [[03-Zettels-Conscious]]
